Market Pulse Archives

April 12, 2021, 7:47 a.m. EDT

Regeneron says its COVID-19 antibody therapy cut risk of infection progression

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Regeneron Pharmaceuticals Inc. (REGN)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Regeneron Pharmaceuticals Inc. /zigman2/quotes/203149337/composite REGN -1.43% gained 1.6% in premarket trading on Monday after the company shared additional positive clinical data from two studies about its COVID-19 monoclonal antibody cocktail. One late-stage trial found that subcutaneous administration of REGEN-COV in recently infected asymptomatic patients lessened the overall risk to progressing to symptomatic infection by 31%. "These data pave the way for REGEN-COV to be used before patients become symptomatic, with a more convenient subcutaneous administration," Dr. Katharine Bar, one of the study's investigators, said in a news release. The treatment, REGEN-COV, is currently authorized only as an intravenous therapy. A second study found that subcutaneous administration of the antibody cocktail reduced the risk of symptomatic infections by 81% in people who shared a household with someone who had recently tested positive for the virus. Regeneron's stock is down 1.6% since the start of the year, while the broader S&P 500 /zigman2/quotes/210599714/realtime SPX -0.85% is up 9.9%.

US : U.S.: Nasdaq
$ 516.22
-7.51 -1.43%
Volume: 683,402
May 18, 2021 4:00p
P/E Ratio
Dividend Yield
Market Cap
$55.80 billion
Rev. per Employee
-35.46 -0.85%
Volume: 2.33B
May 18, 2021 5:16p

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.